Skip to main content

Table 1 Baseline characteristics

From: Evaluation of cardiovascular biomarkers In HIV-infected patients switching to abacavir or tenofovir based therapy

Parameter

ABC/3TC (n = 20)

TDF/FTC (n = 20)

Mean age (SD), years

50 (11.9)

46 (8.7)

Male sex, n (%)

11 (55.0)

14 (70.0)

Active smokers, n (%)

6 (30.0)

9 (45.0)

Mean weight (SD), kg

73.2 (12.1)

74.9 (16.3)

Mean BMI (SD), kg/m2

25.2 (2.1)

25.0 (4.3)

Mean systolic blood pressure (SD), mmHg

133 (21.9)

135 (15.1)

Mean diastolic blood pressure (SD), mmHg

85 (10.9)

84 (9.4)

Median total cholesterol (IQR), mmol/L

5.7 (5.3-6.7)

5.35 (4.8-6.0)

Median LDL cholesterol (IQR), mmol/L

3.8 (3.1-4.3)

3.2 (2.6-4.0)

Median HDL cholesterol (IQR), mmol/L

1.3 (1.1-1.9)

1.2 (1.0-1.7)

Median triglyceride (IQR), mmol/L

1.5 (1.2-2.0)

1.4 (1.0-2.0)

Mean fasting plasma glucose (SD), mmol/L

5.4 (0.52)

5.4 (0.38)

Zidovudine/lamivudine at baseline, n (%)

20 (100)

20 (100)

PI at baseline, n (%)

6 (30.0)

6 (30.0)

Efavirenz at baseline, n (%)

11 (55.0)

9 (45.0)

Nevirapine at baseline, n (%)

3 (15.0)

5 (25.0)

Mean CD4+ cell count (SD), cells/mm2,

567 (256)

540 (206)

Median duration of HAART exposure (IQR), months

86.5 (54.5-125)

106.5 (50.5-130)

Median time since HIV-diagnosis (IQR), months

127 (96.5-140.5)

122 (89-179)

Median Framingham score (IQR)

3 (0-6)

4 (1-7)

Median estimated 10-year cardiovascular risk a.m. Framingham (IQR), %

7 (3-10)

6 (3-11)

  1. BMI = body mass index; PI = protease inhibitor; HAART = highly active antiretroviral therapy; HIV = human immunodeficiency virus.
  2. Normally distributed data are presented as means with standard deviation (SD) in parenthesis. Skewed data are presented as medians with interquartile range (IQR) in parenthesis.